Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx reported strong first-quarter results for 2021, achieving $67.4 million in revenue, a 76% increase year-over-year. The company provided around 33,200 AlloSure and AlloMap patient results, with over 60 U.S. transplant centers adopting AlloSure Kidney protocols. A successful public offering raised approximately $188.7 million, boosting total cash and equivalents to $374.3 million. CareDx has increased its full-year revenue guidance to between $270 million and $280 million, reflecting continued growth in the transplant ecosystem.
CareDx, Inc. (Nasdaq: CDNA) announced the presentation of 15 heart abstracts at the ISHLT Annual Meeting on April 24-28, 2021. The company will showcase a total of 22 abstracts, reflecting its leadership in cardiothoracic care. Notably, a virtual symposium titled “HeartCare: The Utility of Multi-Modality in Transplant Patient Care” will occur on April 25 from 11:30 a.m. to 12:30 p.m. Eastern Time. Presented by experts, the research emphasizes innovative diagnostics for heart transplant rejection detection.
CareDx, Inc. (Nasdaq: CDNA) has announced that Medicare coverage for its transplant testing services remains unchanged under a new universal coverage policy by Palmetto MolDx. The policy reaffirms patient access to services essential for managing organ transplant care. CareDx’s AlloMap and AlloSure tests, which are critical for identifying organ rejection, have been validated through rigorous studies. This continued coverage supports CareDx's mission in enhancing patient care and solidifies its role as a leader in precision medicine.
CareDx (Nasdaq: CDNA) announced its participation in the upcoming International Society of Heart and Lung Transplantation Annual Meeting from April 24-28, 2021, where it will present 22 clinical abstracts, focusing on its AlloSure Lung surveillance technology for lung transplant patients. This technology, expanding on previous successes in heart and kidney transplants, utilizes donor-derived cell-free DNA to non-invasively assess allograft injury. Notably, seven abstracts will detail its clinical utility in lung transplantation, highlighting significant ongoing research.
CareDx, Inc. (Nasdaq: CDNA) announced it will report its first quarter 2021 financial results after market close on May 5, 2021. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for investors and analysts to discuss these results.
Interested parties can join the call by dialing 877-705-6003 for domestic or 201-493-6725 for international calls, referencing Conference ID: 13718586. A live webcast will also be available on CareDx's website.
CareDx, a leader in precision medicine, has announced the hosting of two symposia at the 2021 European Federation for Immunogenetics and Histocompatibility Conference (EFI) from April 21-23, 2021. The sessions will focus on pioneering data in HLA typing and post-transplant surveillance aimed at enhancing transplant patient care. With a total of eight abstracts and one oral presentation highlighting innovations in AlloSeq and QTYPE portfolios, the company aims to improve outcomes in organ transplantation and demonstrate its leadership in the field.
CareDx, Inc. (Nasdaq: CDNA) will exhibit at the 29th Annual UNOS Transplant Management Forum from April 19-22, 2021. On April 20, 2021, at 11:00 a.m. EDT, they will host a symposium titled “Providing Personalized Care for Every Step on the Transplant Journey.” Key topics include pre-transplant care with TX Connect, quality care with XynQAPI, and post-transplant care with AlloSure® dd-cfDNA. CareDx aims to provide integrated digital solutions to improve transplant patient care, highlighted by the recent acquisition of TX Connect.
CareDx, Inc. (CDNA) has launched a next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden, aimed at supporting research in vaccine and drug development. This HLA typing service, powered by AlloSeq Tx17, offers superior gene content and efficient testing capabilities. The service has already been engaged by a top global pharmaceutical company. CareDx is focusing on expanding its global presence and enhancing support for drug development research, enhancing patient care worldwide.
CareDx (Nasdaq: CDNA) will participate in the National Kidney Foundation's 2021 Spring Clinical Meetings from April 6-10, 2021. The company will host a virtual exhibitor showcase titled “Next Generation Care for Kidney Transplant Patients” on April 6, featuring experts like Dr. Christopher Boshkos and Dr. Matthew Weir discussing AlloSure, a standard for kidney transplant surveillance. Additionally, CareDx will sponsor a CME program on April 8 focusing on acute rejection in kidney transplantation, showcasing leading medical professionals' insights.
CareDx, a precision medicine company, has recently announced key leadership appointments to bolster its growth and enhance the patient experience in transplant healthcare. Reg Seeto, President and CEO, emphasized a commitment to innovation and patient-focused integrated digital offerings. New hires include Titte R. Srinivas, M.D., as VP of Digital Development, and Steven Stone, Ph.D., as VP of KidneyCare. Promotions include Marica Grskovic, Ph.D., to VP of Cell Transplant Therapy, reflecting the company’s dedication to improving transplant patient care.
FAQ
What is the current stock price of CareDx (CDNA)?
What is the market cap of CareDx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
